Archive: Raymond J. March
Raymond J. March is a Research Fellow at the Independent Institute.
Banning E-Cigarette Sales Will Do More Harm than Good
Efforts to ban vaping are extremely unlikely to succeed and may push consumers toward harmful alternatives.
How Government Prolonged the Lobotomy
While the lobotomy offers a cautionary tale of medicine gone astray, it should also provide a cautionary tale of the harmful consequences of state-assisted health policies.
New Study Finds FDA in Contempt of the U.S. Constitution
The vast majority of agency regulations were passed by “low-level officials and employees with no authority to issue rules.”
Worried About Big Pharma? Then Reduce the FDA’s Regulatory Power.
To compete for FDA attention, drug makers now needed a way to navigate new safety hurdles to have their products approved.
San Francisco’s Vaping Ban Is Doomed To Go Up in Smoke
Government efforts to regulate away vices can also motivate more dangerous or unhealthy behaviors.
Right-to-Try Legislation Helps Patient Battling Bone Cancer
After receiving access to experimental treatments, Natalie’s condition improved substantially.
FDA Approves Ketamine-Based Drug to Treat Difficult Cases of Depression
Although much work remains to reverse the DEA’s overzealous scheduling system, Ketamine-based treatment for mental illness is another step in the right direction.
Healthcare Needs Price Competition, Not Just Transparency
Efforts to make healthcare costs more transparent are a good start. But transparency is no substitute for competition.
Competition is the Key to Reducing Insulin Prices
Not More Government Involvement
Evidence suggests that competition, not politicians, would provide the best chance to help diabetics obtain their life-prolonging medication.
Right-to-Try’s First Rescue
A Patient with Terminal Brain Cancer Gets Treatment
Signed into law in May, national right-to-try legislation allows patients with terminal illnesses to access experimental treatments with only the permission of their physicians and the drug provider.